Gavin Bennett

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Papillary Thyroid

Solid Phase Extraction

Escherichia Coli

Top Venues

Molecular cancer therapeutics

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Babar Bashir, Judy S Wang, Gerald S Falchook, Elisa Fontana, Hendrick-Tobias Arkenau, Louise Carter, Rachel Galot, Bristi Basu, Alastair P Greystoke, Vivek Subbiah, Debra L Richardson, Hanna Orr, Gavin Bennett, Rajiv Sharma, Hongmei Xu, Paola Paganoni, Cong Xu, Carly Campbell, Meredith A McKean
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Joseph A Tweed, Fern Adams-Dam, Jane Allanson, Kevin Holmes, Ryan Senior, Hongmei Xu, Mengyao Li, Gavin Bennett, Phil Jeffrey
Bioanalysis of the Bicycle ® toxin conjugate BT5528 and released monomethyl auristatin E via liquid chromatography-tandem mass spectrometry. Bioanalysis (2023)
Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma E Mudd, Helen Harrison, Paul J Beswick, Katerine van Rietschoten, Sophie M Watcham, Heather S Scott, Amy N Brown, Peter U Park, Carly Campbell, Eric Haines, Johanna Lahdenranta, Michael J Skynner, Phil Jeffrey, Nicholas Keen, Kevin Lee
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Molecular cancer therapeutics 21 (12) (2022)
Gavin Bennett, Amy N Brown, Gemma E Mudd, Philip Huxley, Katerine Van Rietschoten, Silvia Pavan, Liuhong Chen, Sophie Watcham, Johanna Lahdenranta, Nicholas Keen
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Molecular cancer therapeutics 19 (7) (2020)